SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
PR Newswire
SAN DIEGO, Nov. 9, 2026
SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans.
Members of the military communities are increasingly being diagnosed with cancer at younger ages and at advanced stages. SOTERIA addresses this critical care gap by providing patient-centric precision oncology navigation and facilitating CLIA-validated germline and somatic sequencing, ensuring that each patient's care is informed by comprehensive molecular data when possible.
"Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them," said Julia Civardi, Founder and CEO of SOTERIA. "Partnering with Tempus enables us to bring state-of-the-art genomic sequencing and AI analytics to our active service members and veterans, turning complex molecular data into clear, actionable treatment options for patients and care teams."
"Collaborating with SOTERIA allows us to put cutting-edge genomic insights directly into the hands of clinicians and their patients when every decision matters most," said Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus. "We are proud to support SOTERIA's mission and help advance precision oncology for our nation's service members and veterans."
"As a member of the Special Operations community, I've seen the immense toll these cancers take," said CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA. "This initiative reflects the best of what's possible when technological innovation and service come together to support our military families."
Through this collaboration, Tempus and SOTERIA will continue to streamline molecular profiling and data integration across SOTERIA's patient cohort, advancing precision oncology research and optimizing care pathways for military community members diagnosed with cancer.
CANCER HUNT INQUIRIES
- Learn more about SOTERIA's Cancer Hunt™ Initiative: https://www.soteriaprecisionmedicine.org/military
- Schedule a consult call with one of SOTERIA's nurse navigators: https://www.soteriaprecisionmedicine.org/book-a-consultation
- Email Contact: support@soteriapmf.org
- Organization Site: https://www.soteriaprecisionmedicine.org
MEDIA CONTACTS
SOTERIA Media Relations
SOURCE SOTERIA Precision Medicine Foundation
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
These Overvalued Stocks Have Plenty of Room to Fall
United States